Abstract
BackgroundUstekinumab (UST)has demonstrated efficacy in pts with active psoriatic arthritis (PsA) at wk24 in the Phase 3, multicenter, PBO-controlled PSUMMIT2 trial. Results through wk52 PSUMMIT 2 are presented herein.Methods312 adults...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have